Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients

• Status: Unknown status
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether the treatment of human menstrual blood-derived mesenchymal stem cells which would be applied to diabetes patients is safe and effective.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: S-Evans Biosciences Co., Ltd.; S-Evans Biosciences Co.,Ltd.
• Collaborators: First Affiliated Hospital of Zhejiang University; Wenzhou Medical University; Zhejiang University; Zhenjiang First People's Hospital

Criteria

Inclusion Criteria:

• male and female patients at the age of 18 to 75.

• agreement to receive written informed consent.

• voluntary submission to the procedures of the study protocol.

• clinical diagnosis is classified to type 1 diabetes(T1DM).

• T1DM duration ≥ 1 and ≤ 20 years from the time of enrollment.

Exclusion Criteria:

• renal dysfunction, eye disease or other organ disease.

• cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months.

• pregnancy

• mental disorders

• hepatitis C, HIV, RPR,active tuberculosis or blood diseases

• any malignancy

• any other severe diseases that could potentially influence the infusion results